/**/ document.writeln("\n\n\n\n\n \n\n\n\n\n \n \n \n\n
\n\n \n
\n \n \n \n \n
 Recent News for Ceragenix Pharmaceuticals Inc.\n \n\n\n\n\n
Nov 20 10:54 PM EST
\n\n\n\n
\n \n
\n \n \n\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n
\n\n Oct 26, 2009 6:00 AM EDT
\n\n \n Second Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM) Antimicrobial Coating Application - Business Wire\n \n \n
\n\n Sep 09, 2009 6:00 AM EDT
\n\n \n NIH Issues $2.87 Million Grant for Development of Ceragenin(TM) Based Drug to Treat Clostridium difficile and Shigella Gastrointestinal Infections - Business Wire\n \n \n
\n\n Sep 01, 2009 6:01 AM EDT
\n\n \n Partner Exercises Option for Exclusive Period to Negotiate Licensing Terms for CeraShield(TM) Antimicrobial Coating Application - Business Wire\n \n \n
\n\n Jul 13, 2006 10:53 AM EDT
\n\n \n Ceragenix Pharmaceuticals, Inc. CEO Featured in Exclusive Interview With WallSt.net - PR Newswire\n \n \n
\n\n Jun 28, 2005 8:30 AM EDT
\n\n \n Ceragenix's New Antibiotic Has Potent Activity Against Vancomycin and Tobramycin Resistant Bacterial Infections - GlobeNewswire\n \n \n
\n\n Jun 27, 2005 12:47 PM EDT
\n\n \n OnSource Corporation Changes Name to Ceragenix Pharmaceuticals - GlobeNewswire\n \n \n
\n
\n\n");